Sarepta Therapeutics has suspended shipments of its Duchenne muscular dystrophy gene therapy, Elevidys, for non-ambulatory patients following a second death linked to acute liver failure. Both cases involved advanced disease-stage patients reliant on wheelchairs. Sarepta is collaborating with experts to develop an enhanced immunosuppression strategy and will consult the FDA regarding safety improvements. These developments underscore ongoing challenges in gene therapy safety for late-stage muscular dystrophy treatment.